POST-COVID SYNDROM: CLINICAL SIGNS AND THEIR FEATURES
DOI:
https://doi.org/10.11603/1811-2471.2021.v.i1.11987Keywords:
COVID-19, persisting symptoms, risk factors, long COVIDAbstract
The aim – to investigate the most common clinical manifestations of post-covid syndrome (PS) and how comorbid states affect the rate of occurrence of this syndrome.
Material and Methods. The search was conducted in PubMed and Medline databases by using keywords in English, listed below.
Results. Because not a lot of time has passed from the beginning of the pandemic, there is limited research available on PS. The main body of those studies were conducted by surveying patients after their initial discharge from the hospital (the shortest time being 2 weeks, and the longest – 24 weeks). Analysis of the results of those studies revealed that symptoms, like weakness, breathlessness and anxiety were seen practically in every patient. Cough, pain in the chest and in other parts of the body, problems with sleep and loss of attentiveness were among less persistent symptoms. Notable was the fact that patients with at least one comorbid state, had a higher risk of developing persistent symptoms of acute COVID-19, lasting from 8 to 18 weeks. As such, severe cases of acute COVID-19 and the development of persistent symptoms were frequently seen in patients suffering from obesity, diabetes, and respiratory distress syndrome. Rates of development of lasting symptoms were higher in older patient groups (50+ year old), compared to younger patient groups (18–34 and 35–49 year old).
Conclusion. The most common symptoms of PS were weakness, breathlessness, and anxiety. These symptoms were seen in all age groups, but their rate of occurrence and duration presumably increases with patients` age. Having at least one comorbid state, increased the patient’s chances of developing PS.
References
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., & Song, Y. (2020). Risk factors associated with acute respiratory distress syndrome and death in patients With Coronavirus DISEASE 2019 pneumonia IN WUHAN, CHINA. JAMA Internal Medicine, 180 (7), 934. doi:10.1001/jamainternmed.2020.0994
Chow, N., Fleming-Dutra, K., Gierke, R., Hall, A., Hughes, M., Pilishvili, T., & Ussery, E. (2020). Preliminary estimates of the prevalence of Selected underlying health conditions among patients With Coronavirus DISEASE 2019 – United States, FEBRUARY 12–March 28, 2020. MMWR. Morbidity and Mortality Weekly Report, 69 (13), 382-386. doi:10.15585/mmwr.mm6913e2
Cai, Q., Chen, F., Wang, T., Luo, F., Liu, X., Wu, Q., & Xu, L. (2020). Obesity and COVID-19 severity in a Designated hospital in Shenzhen, China. Diabetes Care, 43 (7), 1392-1398. doi:10.2337/dc20-0576
Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people with certain medical conditions. 2020 Retrieved from: https://www. dc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
Corticosteroids for COVID-19. (2020, September 2). Retrieved from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1
Eli Lilly and Company Attention: Christine Phillips, PhD, 2021. Retrieved from https://www.fda.gov/media/ 143602/download
Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare, 2014. Report on the deliberation results . Retrieved from https://www.pmda.go.jp/files/000210319.pdf
Sehailia, M., & Chemat, S. (2020). Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 AND lys31-binding hotspots OF SARS-COV-2 spike protein THAN HYDROXYCHLOROQUINE: Potential repurposing of artenimol FOR COVID-19. Journal of Biomolecular Structure and Dynamics, 1-11. doi:10.1080/07391102.2020. 1796809
Cao, R., Hu, H., Li, Y., Wang, X., Xu, M., Liu, J., & Zhong, W. (2020). Anti-sars-cov-2 potential of artemisinins in vitro. ACS Infectious Diseases, 6 (9), 2524-2531. doi:10.1021/acsinfecdis.0c00522
Chaccour, C., Casellas, A., Blanco-Di Matteo, A., Pineda, I., Fernandez-Montero, A., Ruiz-Castillo, P., & Fernández-Alonso, M. (2021). The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with Non-severe covid-19: A Pilot, double-blind, PLACEBO-CONTROLLED, randomized clinical trial. EClinicalMedicine, 32, 100720. doi:10.1016/j.eclinm.2020.100720
COVID-19 Therapeutic Alert: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults), 2021. Retrieved from https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103134
The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Tocilizumab for the Treatment of COVID-19, 2021. Retrieved from https://www.covid19treatmentguidelines.nih.gov/statement-on-tocilizumab/
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell. Res., 30 (3), 269-271. DOI: 10.1038/s41422-020-0282-0
Joyner, M.J., Senefeld, J.W., Klassen, S.A., Mills, J.R., Johnson, P.W., Theel, E.S., & Casadevall, A. (2020). Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. August 12, 2020. medRxiv, 2020, 20169359. DOI: https://doi.org/10.1101/2020.08.12.20169359 Preprint
Caly, L., Druce, J.D., Catton, M.G., Jans, D.A., & Wagstaff, K.M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res., 78, 104787. DOI: 10.1016/j.antiviral.2020.104787
National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. April 21, 2020. Retrieved from: https://www.covid19treatmentguidelines.nih.gov
Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. 2020 Retrieved from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management
Al-Jahdhami, I., Al-Naamani, K., & Al-Mawali, A. (2021). The post-acute COVID-19 SYNDROME (Long COVID). Oman Medical Journal, 36 (1). doi:10.5001/omj.2021.91
Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., & Gu, X. (2021). 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet, 397 (10270), 220-232. DOI: 10.1016/ S0140-6736(20)32656-8
Garrigues, E., Janvier, P., Kherabi, Y., Le Bot, A., Hamon, A., Gouze, H., & Nguyen, Y. (2020). Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect., 81 (6), e4-e6.
Tenforde, M.W., Kim, S.S., Lindsell, C.J., Rose, E.B., Shapiro, N.I., Files, D.C., & Feldstein, L.R. (2020). Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March–June 2020. MMWR Morb. Mortal. Wkly. Rep., 69 (30), 993-998. DOI: http://dx.doi.org/10.15585/mmwr.mm6930e1
Halpin, S.J., McIvor, C., Whyatt, G., Adams, A., Harvey, O., McLean, L., & Sivan, M. (2021). Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J. Med. Virol., 93 (2), 1013-1022.
Carfì, A., Bernabei, R., & Landi, F. (2020). Persistent Symptoms in Patients After Acute COVID-19. JAMA, 324 (6), 603-605. DOI: 10.1001/jama.2020.12603
Barin, B., Yoldascan, B. E., Savaskan, F., Ozbalikci, G., Karaderi, T., & Çakal, H. (2021). Joint investigation OF 2-month Post-diagnosis igg antibody levels and psychological measures for assessing longer term multi-faceted Recovery Among COVID-19 cases in Northern Cyprus. Frontiers in Public Health, 8. doi:10.3389/fpubh.2020.590096
Mart, M.F., & Ware, L.B. (2020). The long-lasting effects of the acute respiratory distress syndrome. Expert Rev. Respir. Med., 14 (6), 577-586. DOI: 10.1080/17476348. 2020.1743182
Leone, N., Courbon, D., Thomas, F., Bean, K., Jégo, B., Leynaert, B., & Zureik, M. (2009). Lung function impairmentand metabolic syndrome: The critical role of abdominal obesity. Am. J. Respir. Crit. Care. Med., 179, 509-516.
Mrigpuri, P., Sonal, S., Spalgais, S., Goel, N., Menon, B., & Kumar, R. (2021). Uncontrolled diabetes mellitus: A risk factor for post COVID fibrosis. Monaldi Arch. Chest. Dis., 91 (1). DOI: 10.4081/monaldi.2021.1607
Hussain A., Bhowmik B., & do Vale Moreira, N.C. (2020). COVID-19 and diabetes: Knowledge in progress. Diabetes Res. Clin. Pract., 162, 108-142.
Ojo, A.S., Balogun, S.A., Williams, O.T., & Ojo, O.S. (2020). Pulmonary fibrosis in COVID-19 survivors: Predictive factors and risk reduction strategies. Pulm. Med., 2020, 6175964. DOI: 10.1155/2020/6175964
Zhao, C., Wong, L., Zhu, Q., & Yang, H. (2018). Prevalence and correlates of chronic diseases in an elderly population: a community-based survey in Haikou. PLOS ONE, 13(6). doi:10.1371/journal.pone.0199006
Sanada, F., Taniyama, Y., Muratsu, J., Otsu, R., Shimizu, H., Rakugi, H., & Morishita, R. (2018). Source of chronic inflammation in aging. Frontiers in Cardiovascular Medicine, 5. doi:10.3389/fcvm.2018.00012
Zhang, X., Meng, X., Chen, Y., Leng, S.X., & Zhang, H. (2017). The biology of aging and cancer: frailty, inflammation, and immunity. Cancer J., 23 (4), 201-205. DOI: 10.1097/ppo.0000000000000270.
Sauer, K.S., Jungmann, S.M., & Witthöft, M. (2020). Emotional and behavioral consequences of the covid-19 pandemic: The role of health anxiety, intolerance of uncertainty, and distress (in)tolerance. International Journal of Environmental Research and Public Health, 17 (19), 7241. doi:10.3390/ijerph17197241
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
